Cyproterone
also Cyproterone acetate, Androcur
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
Cyproterone, also known by its developmental code name SH-80881, is a steroidal antiandrogen which was studied in the 1960s and 1970s but was never introduced for medical use. It is a precursor of cyproterone acetate (CPA), an antiandrogen, progestin, and antigonadotropin which was introduced instead of cyproterone and is widely used as a medication. Cyproterone and CPA were among the first antiandrogens to be developed.
Read “Cyproterone” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Effect of cyproterone acetate on rate of hair growth in hirsute females
- Cyproterone acetate for hirsutism
- The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females
- The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review
- Effect of cyproterone acetate on hair growth, sebaceous secretion and endocrine parameters in a hirsute subject
- Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents
- The effect of testosterone, cyproterone acetate, and minoxidil on hair loss in the androchronogenetic alopecia mouse
- A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism
- Effect of Cyproterone Acetate Orally on Hair Density and Diameter and Endocrine Factors in Women with Idiopathic Hirsutism
- Hair growth and androgen responses in hirsute women treated with continuous cyproterone acetate and cyclical ethinyl oestradiol
- Anti-androgen therapy in polyendocrine metabolic ovary syndrome (PMOS, formerly PCOS): efficacy, safety, and phenotype-oriented clinical decision-making
- Cyproterone acetate for hirsutism
- Endocrine Management of Adult Gender-Dysphoric/Gender-Incongruent Persons: A Clinical Practice Guideline from Endocrine Society of India
- Remarkable findings in male pattern baldness: sugar molecule 2dDR offers hope for hair regrowth
- Pericardial Disorders Occurring during Open Label Study of 3747 Patients Treated with Systemic Minoxidil
- Bicalutamide in Dermatology: A Narrative Review
- Top cited articles in dissecting cellulitis of the scalp: A bibliometric analysis
- What you need to know about gender‐affirming healthcare
- Contraception for Women with Polycystic Ovary Syndrome: Dealing with a Complex Condition
- Comment on “Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients”
Posts 12
- Is there such a thing as oral RU58841?
- Fin and Dut Cause Dry Eye Disease? Nope
- Seriously concerning sides effects occurring on RU58841
- Why is nobody talking about topical Spironolactone?
- What is everyone's stack and why?
- HUGE WARNING ABOUT PROPECIA/FINASTERIDE
- If increased prolactin causes hair loss, why do DHT inhibitors work so well?
- Less popular medically proven ways to treat hair loss
- Any current RU58841 user experiences? I just added it to my nuclear stack.
- PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
- Does Ru58841 work? How long should I wait to see results?
- 15 Week Update of Oral Consumption of Topical Minoxidil. 3 drops Keeps 5% (3.75mg) 2x per day with comparison.